Radiopharmaceuticals have three main ingredients. The first is the radioisotope, which delivers the radiation necessary for treatment. The second component is a specially designed carrier molecule which directs the radioisotope to the cancer cells. The third is the chelator, which securely binds the radioisotope to the carrier, ensuring stability throughout the process.


About Navigo Proteins
Navigo Proteins is a near-clinical fast-growing biopharmaceutical company focused on Precision Medicine and particularly next generation radiotheranostics based on using its proprietary Affilin® platform. Affilins® are novel target-binding proteins, combining the advantages of antibodies and peptides.
The growing Affilin® portfolio, backed by unique pre-clinical data, tackles key challenges in targeted therapeutics, achieving exceptional tumor-specific accumulation and favorable biodistribution. Collaborations in the Radiopharmaceutical industry with strong players like ITM, as well as in-house programs drive the development of Affilins® for targeted radioligand therapy and imaging.

The ultimate aim at Navigo Proteins is to deliver best-in-class therapies and lifesaving products to patients faster. The high modularity of the Navigo platform allows faster innovation cycles building on proven and tested components.


About SCK CEN
SCK CEN is one of the largest research institutions in Belgium. Every day, more than 900 employees dedicate themselves to developing peaceful applications for radioactivity. SCK CEN's research activities focus on three main areas: innovative nuclear systems, nuclear waste management and dismantling and the resolute fight against cancer. SCK CEN is world-renowned and shares its knowledge through countless publications and training courses, so that this pool of exceptional competence can be maintained.

Back to HCB News

Most Read Announcements Homepage